


AMENDMENTS TO THE CLAIMS

The following is a complete, marked up listing of revised claims with a status identifier in parentheses, underlined text indicating insertions, and strikethrough and/or double brackets indicating deletions.

Listing of the Claims

1. (CURRENTLY AMENDED) A compound of the following ~~general~~ formula (I):



(I)

wherein

R₂ designates hydrogen, Me, Et, CHO, CN, OH, OMe, COR₉, COOR₉, CONHR₉ or CSNHR₉, whereby R₉ denotes (C₁-C₄) alkyl;

R₅ designates hydrogen, (C₁-C₄) alkyl, OH, (C₁-C₄) alkoxy, OCF₃, trifluoromethyl or halogen;

R₆ designates Me, (C₁-C₄) alkoxy, OCF₃, SMe or SEt;

n is 1 or 2;

R₃' ~~an~~ and R₅' each independently designate OH, Me, Et, OMe, OCF₃, trifluoromethyl or halogen;

U designates N or CR₂', whereby R₂' denotes hydrogen, (C₁-C₄) alkyl, (C₁-C₄) alkoxy, trifluoromethyl or halogen;

V designates N or CR₄', whereby R₄' denotes hydrogen, (C₁-C₆) alkoxy, (C₁-C₆) alkyl, OH, trifluoromethyl or halogen;

W designates N or CR₆', whereby R₆' denotes hydrogen, (C₁-C₄) alkyl, (C₁-C₄) alkoxy, trifluoromethyl or halogen; ~~and~~ or pharmaceutically acceptable ~~salts~~ salt thereof.

2. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₂ designates Me, OH, CN, CHO, COR₉ or COOR₉.

3. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₂ designates Me, CN, CHO or COMe.

4. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₅ designates hydrogen, Me, OMe or halogen.

5. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₆ designates OMe or OEt.

6. (CURRENTLY AMENDED) A compound according to claim 1, wherein R₅ designates hydrogen or OMe, ~~preferably hydrogen~~; and R₆ designates OMe.
7. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₃' and R₅' each independently designate chloro, bromo, Me or OMe.
8. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R₃' and R₅' are identical; or R₃' designates chloro or bromo, and R₅' designates OMe.
9. (PREVIOUSLY PRESENTED) A compound according to claim 7, wherein R₃' and R₅' designate both chloro or both bromo.
10. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein U and W designate CH and V designates CR₄'.
11. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R₄' designates hydrogen, chloro, bromo, Me or OMe.
12. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R₃', R₄' and R₅' designate OMe; or R₃' designates chloro and R₄' and R₅' designate OMe; or R₄' designates hydrogen and R₃' and R₅' designate both chloro or both bromo.

13. (CURRENTLY AMENDED) A-The compound according to claim 1, wherein the compound is one selected from the group consisting of, ~~which is~~ 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-

ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline,

trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, ~~or a~~ and pharmaceutically acceptable ~~salt~~ salts thereof.

14. (PREVIOUSLY PRESENTED) A compound according to claim 1, which is the (R) - or (S)-enantiomer.

15. (CURRENTLY AMENDED) A medicament, comprising the compound as ~~defined in~~ according to claim 1, ~~for use as a medicament.~~

16. (CURRENTLY AMENDED) ~~Use of a compound as defined in claim 1, for the preparation of~~ A method of preparing a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, comprising utilizing the compound according to claim 1.

17. (CURRENTLY AMENDED) The ~~use method~~ according to claim 16, wherein the disease is selected from cell proliferate diseases ~~such as~~including cancer, atherosclerosis, restenosis, inflammatory diseases ~~such as~~including psoriasis, and autoimmune diseases ~~such as~~including rheumatoid arthritis, and transplant rejection.

18. (CURRENTLY AMENDED) A method of treatment or prophylaxis of a disease leukemia, breast cancer, melanoma cancer or prostate cancer in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in need of such treatment or prophylaxis, comprising administering to said subject an amount of ~~a~~the compound of formula (I) ~~as defined in~~according to claim 1 in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

19. (CANCELLED)

20. (CURRENTLY AMENDED) A pharmaceutical composition, comprising: a ~~the~~ compound of formula (I), or ~~a~~the pharmaceutically acceptable salt thereof ~~as defined in~~according to claim 1; and a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (CURRENTLY AMENDED) ~~Articles~~ A kit, comprising: containing a
the compound of the formula (I) or ~~a~~ the pharmaceutically acceptable
salt thereof ~~as defined in~~ according to claim 1, and a chemotherapeutic
agent, as a combination for the simultaneous, separate or successive
administration in the therapy of a disease in which down-regulation or
inhibition of the expression or function of the IGF-1 receptor is beneficial.

22. (CURRENTLY AMENDED) ~~Use of a compound of the formula (I) or a~~
~~pharmaceutically acceptable salt thereof as defined in claim 1, as a~~
~~pharmacological tool in the development and standardization of in vitro and~~
~~in vivo test systems for the evaluation of~~ A method of evaluating the effects of
~~inhibitors of cell cycle activity in laboratory animals~~ interfering with cell
division by blocking cells in prophase of the mitotic cycle, comprising
utilizing the compound according to claim 1 as a pharmacological tool in the
development and standardization of *in vitro* and *in vivo* test systems for the
cells.

* * * * *

END OF CLAIM LISTING